Top Tweets for #ash2026
👇👇👇 #ASH2026
Here are the top 11 abstracts and (all were scored fairly) at #ASH2026 that I believe will show main impact :
1. AQUILA · Abstract #112 · 9.8/10
1/3 Does treating high-risk smoldering myeloma help patients live longer? My #1 #ASH26 abstract is AQUILA (#112), daratumumab vs active monitoring in high-risk SMM. My score: 9.8/10.
2/3 Among 390 randomized patients, 7-year overall survival was 87.8% with daratumumab vs 78.7% with monitoring. That’s a 9.1-point absolute difference. Median PFS was 82.5 vs 34.9 months.
3/3 This changes my conversation with an asymptomatic patient. Once we confirm high-risk SMM and exclude active myeloma, we can weigh up to 3 years of treatment against a measurable survival benefit.
#mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @Larvol @OpenMedKate @oncodaily
Heading to #ASH2026 in New Orleans?
K36 Therapeutics looks forward to connecting with #MultipleMyeloma investigators, researchers & pharma partners to explore collaborations advancing novel NSD2/MMSET-targeted therapies for high-risk myeloma.
Let's connect! 📩 [email protected]
🇨🇳Simcere’s SIM0500 (CD3/BCMA/GPRC5D tri-specific) Phase 1 data at #ASH2026 abstract 265
First clinical disclosure of the tri-specific antibody (monovalent BCMA + bivalent GPRC5D, optimized CD3 affinity).
Phase 1 (n=38 RRMM, ≥3 prior lines, 12 dose levels):
- Median follow-up 7.53 months
- No DLTs
- CRS: 44.7% (mostly Grade 1); no Grade ≥3; no ICANS
- Infections: 39.5% (13.2% Grade 3)
- No treatment discontinuations due to toxicity
Efficacy (Dose levels 8–12, n=16 evaluable):
- ORR 81.3%
- VGPR 75%
- CR 37.5%
- All 9 evaluable patients achieved MRD negativity
- Median time to response: 4.7 weeks
- 2/3 patients with prior BCMA/GPRC5D-targeted therapy achieved VGPR
Higher dose cohorts (10–12) showed ORR of 85.7%. Free serum BCMA reduced by 93.2% at C2D1.
iCMLf’s abstract accepted for #ASH2026!
Professor Susan Branford will present insights from the iCMLf Genomics Alliance on the HARMONY Platform.
📆 Saturday, December 12th, 9.30am-11.00am (local time New Orleans)
📍 Room: MMCNO - Hall B
Here are the top 11 abstracts and (all were scored fairly) at #ASH2026 that I believe will show main impact :
1. AQUILA · Abstract #112 · 9.8/10
1/3 Does treating high-risk smoldering myeloma help patients live longer? My #1 #ASH26 abstract is AQUILA (#112), daratumumab vs active monitoring in high-risk SMM. My score: 9.8/10.
2/3 Among 390 randomized patients, 7-year overall survival was 87.8% with daratumumab vs 78.7% with monitoring. That’s a 9.1-point absolute difference. Median PFS was 82.5 vs 34.9 months.
3/3 This changes my conversation with an asymptomatic patient. Once we confirm high-risk SMM and exclude active myeloma, we can weigh up to 3 years of treatment against a measurable survival benefit.
#mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @Larvol @OpenMedKate @oncodaily
𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗣𝗮𝗴𝗲𝘀 𝗧𝘂𝗲𝘀𝗱𝗮𝘆 | #ASH2026 edition
𝟭𝟬 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁𝘀 𝗜’𝗺 𝘄𝗮𝘁𝗰𝗵𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗜𝗻𝗱𝗶𝗮
With teclistamab (Tec), elranatamab (Elra), talquetamab (Tal) and SC Dara in our toolkit, my questions are about sequencing, duration, safety and access.
𝟭. 𝗠𝗼𝗻𝘂𝗺𝗲𝗻𝗧𝗔𝗟-𝟲 | #426
At 13.4 months’ median follow-up, Tec+Tal vs EPd/PVd: PFS HR 0.11; Tal+Pom also improved PFS/OS. ~80% were anti-CD38-refractory. Watch the planned 26-cycle bispecific cap and immunoglobulin replacement burden.
𝟮. 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝘀𝗠𝗠-𝟱 | #424
Elra vs DPd: PFS HR 0.56. Only 5.9% had prior anti-CD38 exposure: important when interpreting this for Dara-refractory relapse.
𝟯. 𝗪𝗵𝗶𝗰𝗵 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗲𝘅𝘁? | #2205
In a retrospective 187-patient series, 136 target-switchers had median PFS ~4 months with the second bispecific. Activity remains possible; the best order is unresolved.
𝟰. 𝗖𝗮𝗻 𝘄𝗲 𝘀𝘁𝗼𝗽 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝘀? | #845
43 selected responders stopped; 12-month treatment-free PFS was 85.4%. Relevant to financial and infectious toxicity; selection bias limits conclusions.
𝟱. 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 | #2275
Modelled 1-year grade ≥3 infection risk: 21.0% with continuous vs 38.3% with observed immunoglobulin replacement. Supportive care belongs in the budget; replacement was not randomized.
𝟲. 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗰𝗲𝗶𝘃𝗲 𝗧𝗮𝗹? | #934
Among 43 IHC-evaluable Tal patients, none of 19 with low/negative GPRC5D responded. Could pretreatment IHC improve selection? Retrospective data need validation.
𝟳. 𝗣𝗘𝗥𝗦𝗘𝗨𝗦 | #111
After ASCT, 236 patients stopped Dara per protocol; lenalidomide continued. Eligibility required ≥24 months maintenance, ≥CR and ≥12 months sustained MRD negativity by serial NGS.
𝟴. 𝗔𝗤𝗨𝗜𝗟𝗔 | #112
In high-risk smoldering MM, 7-year OS: 87.8% vs 78.7% with 3 years of SC Dara vs monitoring. Risk definitions and reliable follow-up are central before treating asymptomatic patients.
𝟵. 𝗕𝗲𝗹𝗮𝗻𝘁𝗮𝗺𝗮𝗯 𝗲𝘆𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 | #419
A 30-patient BelaRd study in newly diagnosed MM tests symptom-guided dosing. Both groups still had eye examinations. A practical implementation question for belantamab.
𝟭𝟬. 𝗘𝗫𝗖𝗔𝗟𝗜𝗕𝗘𝗥-𝗥𝗥𝗠𝗠: 𝗶𝗯𝗲𝗿𝗱𝗼𝗺𝗶𝗱𝗲 | #114
IberDd vs DVd: 10⁻⁵ flow MRD-negative CR, 41.1% vs 20.7%. PFS results await presentation. A CELMoD future-access watch: 84.3% grade 3/4 neutropenia; anti-CD38-refractory patients excluded.
For MRD, 10⁻⁵ is not 10⁻⁶; matching sensitivity also does not automatically make flow and NGS interchangeable for a trial’s treatment decisions.
These are abstracts to examine closely, with fuller data still to come.
#TurningPagesTuesday #MMsm
🩸 Join HemeHub this December for our Post ASH 2026 live webinar series!
Explore the latest updates in Leukemia, Lymphoma, Classical Hematology, and Myeloma through expert-led sessions.
🔗 Register: https://t.co/TJfE4YDEpq
#HemeHub #ASH2026 #ASH26 #Hematology #HematologyOncology #HemeOnc #Myeloma #Leukemia #Lymphoma
🩸 Schedule Update for HemeHub’s Post-ASH 2026 Live Webinar Series!
Our Myeloma session will now take place on December 23, while the Leukemia, Lymphoma, and Classical Hematology sessions remain scheduled for December 21.
🔗 Register: https://t.co/TJfE4YDEpq
#HemeHub #ASH2026 #PostASH2026 #Hematology #HematologyOncology #Myeloma #Leukemia #Lymphoma
🩸 #ASH26 | #AML Abstracts to Watch (Oral)
My current list of 11 AML abstracts to watch at #ASH2026 👇 #leusm
A mix of potentially practice-changing frontline trials, menin inhibitors, MRD, and novel approaches in both younger and older patients.
1️⃣ Ivosidenib + intensive chemotherapy in newly diagnosed IDH1-mutated AML
HOVON150/AMLSG29-18, phase 3
Superior event-free survival
📄 Abstract 0001, Press Program
📅 Sun Dec 13 | 7:00 AM CT
⚠️ Oral/plenary slot not yet confirmed
🔗 https://t.co/HAiAem9IzK
2️⃣ Gilteritinib vs midostaurin in newly diagnosed FLT3-mutated AML
Subgroup analysis from HOVON156/AMLSG28-18/pasha
📄 Abstract 56 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/vnNwomzMZ7
3️⃣ Bleximenib in R/R AML with KMT2A rearrangements or NPM1 mutations
Topline results from phase 2 CAMELOT-1
📄 Abstract 661 | Session 616
📅 Sun Dec 13 | 4:30 PM
📍 Hall B
🔗 https://t.co/Das1necevM
4️⃣ Cladribine + LDAC + venetoclax vs intensive chemotherapy (7+3)
Patients ≥60 years with newly diagnosed AML
📄 Abstract 57 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/vuvS9OfmdF
5️⃣ Can we stop HMA + venetoclax?
Discontinuation of hypomethylating agent + venetoclax in newly diagnosed AML with undetectable MRD
📄 Abstract 1009 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/MiP4Z7F5BL
6️⃣ Sonrotoclax + azacitidine across ELN 2024 genetic risk groups
Treatment-naive AML unfit for intensive chemotherapy
📄 Abstract 60 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/gU3WGMcyAm
7️⃣ Venetoclax + 3-day multi-frequency decitabine vs AZA + VEN
Older adults with newly diagnosed AML, updated randomized results
📄 Abstract 1012 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/L7cHhkZ4IF
8️⃣ Whole-genome-informed AML MRD testing
Prospective multicenter validation, MEASURE
📄 Abstract 390 | Session 619
📅 Sat Dec 12 | 4:00 PM
📍 Great Hall AD
🔗 https://t.co/XPb38cdFAW
9️⃣ VEN + AZA vs daunorubicin + cytarabine induction
Young adults with ELN adverse-risk AML, phase 2b
📄 Abstract 1010 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/T8URfhrzzg
🔟 Ziftomenib + gilteritinib in R/R NPM1- and FLT3-co-mutated AML
First results from phase 1 KOMET-008
📄 Abstract 66 | Session 617
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall AD
🔗 https://t.co/nTnyI2myj8
11/12
1️⃣1️⃣ FLAI-G frontline in younger FLT3-mutated AML
Fludarabine + high-dose cytarabine + idarubicin + gilteritinib
First interim analysis, phase 2 GIMEMA AML2924
📄 Abstract 903 | Session 617
📅 Mon Dec 14 | 2:45 PM
📍 Great Hall BC
🔗 https://t.co/OwFJZBjAnr
Lots to watch at #ASH26 in AML.
Particularly interested in the randomized frontline data, evolving role of menin inhibition, MRD-guided treatment decisions, and whether lower-intensity approaches can continue challenging conventional intensive chemotherapy.
Which AML abstracts are on your must-see list?
#AML #Leukemia #ASH26
#ASH2026: Pullarkat et al report real-world outcomes with duvelisib in a real-world cohort of 328 patients with nodal PTCL:
- ORR 46%, CRR 32%
- In TFH lymphoma: ORR 58%, CRR 46%
- Median duration of response 250 days
- 16% proceeded to alloSCT
https://t.co/UHtl0KGBoX
#ASH2026: Eche-Ugwu et al & the PETAL consortium report the first study to report HRQL outcomes in patients with PTCL. Rates of pre-treatment HRQL similar to other lymphoma subtypes. Congratulations to the authors for working to address this important gap.
https://t.co/ABFDRgupEA
#ASH2026 iMMagine-1 update: Anito-cel in RRMM (n=117, median follow-up 18 mo). ORR 96%, CR/sCR 75%, MRD− (10⁻⁶) 76% of evaluable pts, 24-mo PFS 58%, OS 84%, ICANS 8%, No delayed/non-ICANS neurotoxicity reported
#ASH2026 NMDP/CIBMTR present:
OPTIMIZE: ⬇️ dose PTCy delivered 88.7% 1-yr survival in mismatched unrelated donor transplants
MEASURE: Genome-informed AML MRD testing achieved 97% sensitivity v. 31% standard care
CIBMTR: MCW-NMDP research collab. https://t.co/qSPPFnyd3k
Fellow #myeloma patients!
I'll be attending #ASH2026 with the @IMFmyeloma Patients at ASH team! ❤️
Follow me for the latest research updates, key takeaways, and the patient perspective.
Have questions you'd like me to explore? Let me know!
#IMFASH26
🩸 Mark your calendars for HemeHub’s Post-ASH 2026 live webinar series this December!
Join us for expert-led updates in Leukemia, Lymphoma, Classical Hematology, and Myeloma.
🔗 Register: https://t.co/TJfE4YEceY
#HemeHub #ASH2026 #ASH26 #Hematology #HematologyOncology #HemeOnc #Myeloma #Leukemia #Lymphoma
🩸 Schedule Update for HemeHub’s Post-ASH 2026 Live Webinar Series!
Our Myeloma session will now take place on December 23, while the Leukemia, Lymphoma, and Classical Hematology sessions remain scheduled for December 21.
🔗 Register: https://t.co/TJfE4YDEpq
#HemeHub #ASH2026 #PostASH2026 #Hematology #HematologyOncology #Myeloma #Leukemia #Lymphoma
📢 Exciting News - Abstracts for #ASH2026 are posted!!!
We are proud to be presenting our research this year investigating our mass spectrometry (MS) based assay for the quantification of soluble B-cell maturation antigen (sBCMA) in multiple myeloma (MM) serum samples.
💡 The study found that our MS-based assay had good correlation to sBCMA ELISA in MM patients, demonstrating the potential to monitor disease burden in MM patients, regardless of their M-protein type.
In addition, we collaborated on a study with Washington University School of Medicine in St. Louis, to describe post-chimeric antigen receptor (CAR) T cell M-protein kinetics, using clonotypic mass spectrometry (CT-MS).
💡 Findings demonstrate that CT-MS is highly sensitive for relapse, with detectable and increasing M-protein in 100% of relapse samples. Achieving undetectable CT-MS was highly dependent on M-protein half-life.
Read the full abstracts here:
4067: Mass Spectrometry Assay to Quantify B-Cell Maturation Antigen in Serum of Patients with Multiple Myeloma: https://t.co/zuok9rRida
4071: M-Protein Kinetics via Clonotypic Mass Spectrometry Following BCMA-Directed CAR T Cell Therapy: https://t.co/0Kpb6dbijn
#MultipleMyeloma #MM #MRD #MinimalResidualDisease #MMSM #CART #BCMA #MassSpec
Last Seen Hashtags on Sotwe
hottub
Seen from Germany
snapchatt(***)**(**)**(*)**filter:videos
Seen from United States
HBDLakshmigopalaswami
Seen from United States
Chinese #crossdress
Seen from India
feriaterapia
Seen from United States
sitahonda
Seen from Netherlands
HBDKayKayMenon
Seen from United States
سوالب_العراق
netorare
Seen from Japan
AnnoyingDrivers
Seen from Netherlands
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.3M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers